SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

INKT

MiNK Therapeutics
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The ASGCT data provides mechanistic validation for agenT-797's dual-mode activity, de-risking the platform and supporting the upcoming Phase 2 trial in acute lung injury. Monitor for preliminary Phase 2 data in 2026, which could be a major catalyst. The broad applicability across oncology and critical care expands the addressable market.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.41
T+0 close · May 12, 2026 · via day close
Latest settled
−3.59%
T+60 · $11.00
Vs SPY
−7.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $11.41entry
  2. T+1 · 6mo ago −3.16%α −3.73% · $11.05
  3. T+5 · 6mo ago −12.01%α −12.08% · $10.04
  4. T+20 · 5mo ago +6.84%α +8.56% · $12.19
  5. T+60 · 3mo ago −3.59%α −7.98% · $11.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.

Key Facts

  • agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
  • Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
  • Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
  • Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.
  • Manufacturing platform scalable: reproducible across multiple batches and donors, producing billions of cells per donor.

Financial Impact

No financial figures disclosed; potential value depends on Phase 2 trial outcomes and eventual commercialization.

revenuemarket cap

Risk Factors

  • Phase 2 trial results may not replicate Phase 1/2 findings.
  • Competition from other cell therapy platforms and existing ARDS treatments.
  • Regulatory and manufacturing scale-up risks for allogeneic cell therapy.
  • Company has limited cash runway (market cap $55M) and may need to raise capital.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292728

Track record

21 reports on INKT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026